Market Cap 10.39B
Revenue (ttm) 14.74B
Net Income (ttm) -634.20M
EPS (ttm) N/A
PE Ratio 3.58
Forward PE 3.95
Profit Margin -4.30%
Debt to Equity Ratio 1.02
Volume 12,754,300
Avg Vol 14,578,876
Day's Range N/A - N/A
Shares Out 1.17B
Stochastic %K 55%
Beta 0.90
Analysts Hold
Price Target $10.91

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
Bears2354
Bears2354 Jun. 23 at 11:28 PM
$CRVS $CDT $DJT $SOAR $VTRS These are the money makers for this year.
0 · Reply
PetrCZE
PetrCZE Jun. 23 at 10:40 AM
$VTRS Before an Indore impact, the SP was approx. 12-13$/share. Indore issue shall be resolved in S2 2025. Once resolved, hope the SP will climb at minimum to those previous levels. Thou, negative impact might be the TACO tariffs. But even those might not last forever... Still betting on this one as long term play...
1 · Reply
JazzyJ03
JazzyJ03 Jun. 13 at 5:23 PM
$VTRS 👀
0 · Reply
SniperPro
SniperPro Jun. 5 at 10:09 PM
$LXRX 💯 Let’s be real — not everyone needs beauty products... But every single person on Earth has a heart, a body, and a real need for medication when health issues arise... 🔥🔥🔥 "NEEDS vs. WANTS" 🔥🔥🔥 Once Inpefa and Pilavapadin gets licensed to big pharma — with the resources and connections to bypass the gatekeepers — they’ll be printing money around the clock... 24/7 Baby!!! 🔥🔥🔥 Business Model and Revenue 🔥🔥🔥 Lexicon has primarily relied on: Milestone payments Royalties Partner funding "Lex’s future is bright, thanks to big pharma partnerships and unlimited (or in-perpetuity) royalties." Cash is KING!!! Two partnership deals confirmed $NVO LX9851 $1B+ and $VTRS Sota ex US/EU $200M + royalties... Who is NEXT ? Today's Conference Transcript : https://in.investing.com/news/transcripts/lexicon-pharmaceuticals-at-jefferies-conference-strategic-partnerships-and-pipeline-progress-93CH-4865505
2 · Reply
ItsCarRamRod
ItsCarRamRod Jun. 5 at 8:46 PM
$VTRS $PFE Crap Pharma is not the place to be for the next 3 1/2 years. Just dying a slow death here.
2 · Reply
Hunting93
Hunting93 Jun. 2 at 8:42 PM
$VTRS Everyone’s chasing hype. Meanwhile, Viatris just quietly delivered positive Phase 3 results for a treatment targeting night driving impairment — a real unmet need, with real people waiting. Profitable. Stable. Undervalued. And now? Innovating. Don’t overlook the boring stock solving real problems. That’s where Buffett would be looking.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 2 at 12:10 PM
$VTRS Viatris announces 'positive' results from Phase 3 trial evaluating MR-142 Viatris announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. This study was conducted under a Special Protocol Assessment agreement with the U.S. FDA. The LYNX-2 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked study, with a total of 199 patients who were randomized to receive either MR-142 or placebo, self-administered in both eyes, nightly, treated and observed over 6 weeks. In summary: Significantly more patients treated in the MR-142 arm achieved the primary endpoint of greater than or equal to15-letter Early Treatment Diabetic Retinopathy Study gain in Mesopic Low Contrast Distance Visual Acuity at Day 15, compared to placebo. Patient-reported functional benefit was observed at Day 15 in difficulty of seeing the road because of oncoming headlights in patients dosed with MR-142 compared to placebo; and in difficulty seeing due to glare when driving at dawn or dusk in patients dosed with MR-142 compared to placebo when assessed by the validated Vision and Night Driving Questionnaire. As per the pre-specified testing, no evidence of tachyphylaxis out to Week 6 of dosing. MR-142 demonstrated a safety profile consistent with previous trials, with no new safety signal identified. LYNX-2 patients will continue to be monitored for long-term safety over 48 weeks.
0 · Reply
Bamaoracle
Bamaoracle May. 31 at 1:31 AM
$VTRS what's up with the high volume today?
0 · Reply
smartkarma
smartkarma May. 30 at 8:01 AM
$VTRS | Viatris Inc: Fast-Acting Meloxicam Development, A $650M Buyback Blitz, & Other Key Developments! "Viatris, formerly known by the ticker VTRS, reported its Q1 2025 earnings, reflecting a careful balance of opportunities and challenges. For this..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/viatris-inc-fast-acting-meloxicam-development-a-650m-buyback-blitz-other-key-developments
0 · Reply
Hunting93
Hunting93 May. 29 at 3:25 PM
$VTRS Wall Street Sees It. Do You? 📈 Top analysts give it a $11.60 target – that’s a +33% upside from here. Stable business. Real cash. Dirt cheap price. Buffett would call this “buying a dollar for 70 cents.” Don’t wait for the crowd. Be early. Be smart
0 · Reply
Latest News on VTRS
Viatris to Participate in Upcoming Investor Conferences

May 22, 2025, 6:59 AM EDT - 4 weeks ago

Viatris to Participate in Upcoming Investor Conferences


Viatris Inc. (VTRS) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:35 AM EDT - 6 weeks ago

Viatris Inc. (VTRS) Q1 2025 Earnings Call Transcript


Viatris' pain drug meets main goals of two late-stage trials

May 8, 2025, 6:36 AM EDT - 6 weeks ago

Viatris' pain drug meets main goals of two late-stage trials


Bears2354
Bears2354 Jun. 23 at 11:28 PM
$CRVS $CDT $DJT $SOAR $VTRS These are the money makers for this year.
0 · Reply
PetrCZE
PetrCZE Jun. 23 at 10:40 AM
$VTRS Before an Indore impact, the SP was approx. 12-13$/share. Indore issue shall be resolved in S2 2025. Once resolved, hope the SP will climb at minimum to those previous levels. Thou, negative impact might be the TACO tariffs. But even those might not last forever... Still betting on this one as long term play...
1 · Reply
JazzyJ03
JazzyJ03 Jun. 13 at 5:23 PM
$VTRS 👀
0 · Reply
SniperPro
SniperPro Jun. 5 at 10:09 PM
$LXRX 💯 Let’s be real — not everyone needs beauty products... But every single person on Earth has a heart, a body, and a real need for medication when health issues arise... 🔥🔥🔥 "NEEDS vs. WANTS" 🔥🔥🔥 Once Inpefa and Pilavapadin gets licensed to big pharma — with the resources and connections to bypass the gatekeepers — they’ll be printing money around the clock... 24/7 Baby!!! 🔥🔥🔥 Business Model and Revenue 🔥🔥🔥 Lexicon has primarily relied on: Milestone payments Royalties Partner funding "Lex’s future is bright, thanks to big pharma partnerships and unlimited (or in-perpetuity) royalties." Cash is KING!!! Two partnership deals confirmed $NVO LX9851 $1B+ and $VTRS Sota ex US/EU $200M + royalties... Who is NEXT ? Today's Conference Transcript : https://in.investing.com/news/transcripts/lexicon-pharmaceuticals-at-jefferies-conference-strategic-partnerships-and-pipeline-progress-93CH-4865505
2 · Reply
ItsCarRamRod
ItsCarRamRod Jun. 5 at 8:46 PM
$VTRS $PFE Crap Pharma is not the place to be for the next 3 1/2 years. Just dying a slow death here.
2 · Reply
Hunting93
Hunting93 Jun. 2 at 8:42 PM
$VTRS Everyone’s chasing hype. Meanwhile, Viatris just quietly delivered positive Phase 3 results for a treatment targeting night driving impairment — a real unmet need, with real people waiting. Profitable. Stable. Undervalued. And now? Innovating. Don’t overlook the boring stock solving real problems. That’s where Buffett would be looking.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 2 at 12:10 PM
$VTRS Viatris announces 'positive' results from Phase 3 trial evaluating MR-142 Viatris announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. This study was conducted under a Special Protocol Assessment agreement with the U.S. FDA. The LYNX-2 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked study, with a total of 199 patients who were randomized to receive either MR-142 or placebo, self-administered in both eyes, nightly, treated and observed over 6 weeks. In summary: Significantly more patients treated in the MR-142 arm achieved the primary endpoint of greater than or equal to15-letter Early Treatment Diabetic Retinopathy Study gain in Mesopic Low Contrast Distance Visual Acuity at Day 15, compared to placebo. Patient-reported functional benefit was observed at Day 15 in difficulty of seeing the road because of oncoming headlights in patients dosed with MR-142 compared to placebo; and in difficulty seeing due to glare when driving at dawn or dusk in patients dosed with MR-142 compared to placebo when assessed by the validated Vision and Night Driving Questionnaire. As per the pre-specified testing, no evidence of tachyphylaxis out to Week 6 of dosing. MR-142 demonstrated a safety profile consistent with previous trials, with no new safety signal identified. LYNX-2 patients will continue to be monitored for long-term safety over 48 weeks.
0 · Reply
Bamaoracle
Bamaoracle May. 31 at 1:31 AM
$VTRS what's up with the high volume today?
0 · Reply
smartkarma
smartkarma May. 30 at 8:01 AM
$VTRS | Viatris Inc: Fast-Acting Meloxicam Development, A $650M Buyback Blitz, & Other Key Developments! "Viatris, formerly known by the ticker VTRS, reported its Q1 2025 earnings, reflecting a careful balance of opportunities and challenges. For this..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/viatris-inc-fast-acting-meloxicam-development-a-650m-buyback-blitz-other-key-developments
0 · Reply
Hunting93
Hunting93 May. 29 at 3:25 PM
$VTRS Wall Street Sees It. Do You? 📈 Top analysts give it a $11.60 target – that’s a +33% upside from here. Stable business. Real cash. Dirt cheap price. Buffett would call this “buying a dollar for 70 cents.” Don’t wait for the crowd. Be early. Be smart
0 · Reply
Hunting93
Hunting93 May. 29 at 3:02 PM
$VTRS Not flashy. Just profitable. 🧠 Warren Buffett once said: “Price is what you pay. Value is what you get.” At under $9, $VTRS gives you value, cash flow, and durability. While others chase hype, we buy businesses. This one’s not a moonshot. It’s a fortress.
1 · Reply
Estimize
Estimize May. 26 at 7:04 PM
Wall St is expecting 0.55 EPS for $VTRS Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/vtrs?chart=historical&metric_name=eps&utm_co
0 · Reply
SniperPro
SniperPro May. 22 at 3:29 PM
$MS $BMY $LXRX $NVO $VTRS Ceo Mike didn’t come to NYC just to linger around the conference—he was here to connect with some of his heavy-hitting pharma friends. Meanwhile, a few well-informed insiders were keeping a close eye on the event, grinning from ear to ear, with deep pockets ready to back Lex’s ongoing research and development journey. Inpefa offers significantly fewer side effects compared to today’s high-revenue competitors, making it an ideal treatment for future generations. Its strong safety profile and ability to meet patient needs make it a key contributor to long-term quality of life. Inpefa—coming soon to a pharmacy near you. To be continued...
0 · Reply
taurus_bullish
taurus_bullish May. 22 at 3:02 AM
$VTRS most hated pharma stock after Pfizer
0 · Reply
ItsCarRamRod
ItsCarRamRod May. 21 at 8:01 PM
$VTRS never doubted we would see a major breakdown in VTRS
0 · Reply
Chortlemethis
Chortlemethis May. 21 at 3:48 PM
$VTRS eps beat, revs beat, PE of about 4, debt being paid down. What the heck does the market not like?
0 · Reply
Estimize
Estimize May. 19 at 2:03 PM
Wall St is expecting 0.55 EPS for $VTRS Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/vtrs?chart=historical&metric_name=eps&utm_co
0 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 15 at 1:43 PM
$LXRX People forget $VTRS deal only kicked in LATE LAST YEAR AFTER UPFRONT PAYMENT OF 25 mil to Lex (and regumatory and sales mikestone and tiered royalties). Sota was just approved in May 2023z VIATRIS HAS NOT FULLY HAD A CHANCE TO INITIATE A FULL ON PUSH FOR THEIR EXCLUSIVE RIGHTS PROMOTION IN FULL BECUASE THE RIGHTS TRANSFERS WERE NOT FULLY THERE UNTIL VERY LATE LAST YEAR. Meaning only maaaybe a month or two for Viatris to really start putting pedal to the metal with Sota promo and sales push.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech May. 15 at 1:06 PM
$LXRX $VTRS $NVO $BIB Two weeks ago. Edelman unofficially giving the new administration a second shot at considering T1D for Sota. Nice. Smells like Biden bias for last decision. Now under Dr Martin Makary at the helm and anti jabby JFK jr, looking good. https://www.linkedin.com/posts/taking-control-of-your-diabetes_update-from-dr-steve-edelman-this-morning-activity-7323060775802064897--mMx?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA
2 · Reply
Chortlemethis
Chortlemethis May. 15 at 2:55 AM
$VTRS I was happy to take advantage of this little dip.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures May. 15 at 12:05 AM
$VTRS CEO purchased 60,000 shares at $8.94 for a total of $536,262. Smith Scott Andrew now owns 292,807 shares. https://ceo-buys.com
1 · Reply
ItsCarRamRod
ItsCarRamRod May. 14 at 2:21 PM
$VTRS it jumped back up into the channel so it can follow it down properly this time.
0 · Reply